

The sequences of oligonucleotides used are:

miR-34a-5p mimic - UGGCAGUGUCUUAGCUGGUUGU (Qiagen)

scrambled miRNA mimic - sequence not available (Qiagen, Lot no.#300637469)

GAPDH, forward, 5'-GGATTTGGTCGTATTGGG-3' and reverse, 5'-GGAAGATGGTGATGGGATT-3'; [1]

KLF4, forward, 5'-GTGCCCCGACTAACCGTTG-3', and reverse primer 5'-GTCGTTGAACTCCTCGGTCT-3''; [2] (*KLF4 α*)

KLF4, forward, 5'-ACGATCGTGGCCCCGGAAAAGGAC-3', and reverse primer 5'-CAACAACCGAAAATGCACCAGCCCCAG-3''; [3] (*KLF4-Total*)

REL-1MB, forward, 5'-GCAAGAAGCTCTCGTGTGCTAG-3', and reverse, 5'-AACATCCCACGAACCACAGCCA-3''; [4]

IL-6, forward, 5'-TCATCACTGGTCTTTTGGAG-3' and reverse, 5'-GTCAGGGGTGGTTATTGC-3''; [5]

IL-1 β , forward, 5'-ACAGATGAAGTGCTCCTTCCA-3' and reverse, 5'-GTCGGAGATTCGTAGCTGGAT-3''; [6]

INOS, forward, 5'-CAGCGGGATGACTTTCCAAG-3' and reverse, 5'-AGGCAAGATTTGGACCTGCA-3''; [7]

TNF- α , forward, 5'-ATGGGCTACAGGCTTGTCCTC-3' and reverse, 5'-CTCTTCTGCCTGCTGCACTTTGTNF-3''; [8]

ARG1, forward, 5'-GGCAAGGTGATGGAAGAAAC-3', and reverse 5'-AGTCCGAAACAAGCCAAGGT-3''; [7]

Caspase-3, forward, 5'-ATGGGAGCAAGTCAGTGGAC-3', and reverse 5'-CGTACCAGAGCGAGATGACA-3''; [9]

LIST OF ANTIBODIES USED:

PRIMARY ANTIBODY - Rabbit Caspase 3 (H-277), Santa Cruz Biotechnology, USA (Cat # sc-7148); Rabbit KLF4, Invitrogen, USA (Cat # PA5-20897); Rabbit Arg, Cloud clone, USA (Cat # PAB120Mu01); Mouse β -actin (C4), Santa Cruz Biotechnology, USA (Cat # sc-47778)

SECONDARY ANTIBODY - HRP conjugated Mouse anti-rabbit IgG (Cat # sc-2357) and Rabbit anti-mouse IgG- κ , Santa Cruz Biotechnology, USA (Cat # sc-358914)

REFERENCES

1. Attia, Y.M., et al., *The FXR agonist, obeticholic acid, suppresses HCC proliferation & metastasis: role of IL-6/STAT3 signalling pathway*. Scientific reports, 2017. 7(1): p. 1-12.
2. Tang, G., et al., *Transcriptional repression of FOXO1 by KLF4 contributes to glioma progression*. Oncotarget, 2016. 7(49): p. 81757.
3. Kim, Y.M., et al., *Effects of mechanical stimulation on the reprogramming of somatic cells into human-induced pluripotent stem cells*. Stem cell research & therapy, 2017. 8(1): p. 1-12.
4. Jin, H., et al., *Investigating resistin like beta (RETNLB) as a tumor promoter for oral squamous cell carcinoma*. Head & Face Medicine, 2021. 17(1): p. 1-10.
5. Zhang, S., et al., *Tumor-associated macrophages promote tumor metastasis via the TGF- β /SOX9 axis in non-small cell lung cancer*. Oncotarget, 2017. 8(59): p. 99801.
6. Lei, H., et al., *Human S100A7 induces mature interleukin1 α expression by RAGE-p38 MAPK-calpain1 pathway in psoriasis*. PLoS One, 2017. 12(1): p. e0169788.
7. Jung, K., et al., *Elevated ARG1 expression in primary monocytes-derived macrophages as a predictor of radiation-induced acute skin toxicities in early breast cancer patients*. Cancer biology & therapy, 2015. 16(9): p. 1281-1288.
8. Devarapu, S.K., et al., *Tumor necrosis factor superfamily ligand mRNA expression profiles differ between humans and mice during homeostasis and between various murine kidney injuries*. Journal of biomedical science, 2017. 24(1): p. 1-11.
9. Yang, C., et al., *Transcriptional activation of caspase-6 and-7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicity*. Cell Death & Differentiation, 2008. 15(3): p. 530-544.